uniQure (NASDAQ:QURE) Price Target Raised to $20.00

uniQure (NASDAQ:QURE) had its price objective increased by analysts at Royal Bank of Canada from $14.00 to $20.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The brokerage currently has an “outperform” rating on the biotechnology company’s stock. Royal Bank of Canada’s target price points to a potential upside of 32.63% from the company’s previous close.

Several other equities research analysts also recently weighed in on QURE. HC Wainwright restated a “buy” rating and issued a $25.00 target price on shares of uniQure in a report on Tuesday. StockNews.com raised shares of uniQure to a “sell” rating in a research note on Wednesday. The Goldman Sachs Group cut their target price on uniQure from $10.00 to $9.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 6th. Cantor Fitzgerald raised their price target on uniQure from $28.00 to $58.00 and gave the stock an “overweight” rating in a research note on Tuesday. Finally, Raymond James raised uniQure from an “outperform” rating to a “strong-buy” rating and upped their price objective for the company from $20.00 to $52.00 in a research report on Tuesday. One analyst has rated the stock with a sell rating, two have given a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, uniQure currently has a consensus rating of “Moderate Buy” and an average target price of $28.33.

uniQure Price Performance

Shares of uniQure stock traded down $0.22 during trading hours on Wednesday, reaching $15.08. The company’s stock had a trading volume of 2,345,300 shares, compared to its average volume of 1,621,595. The firm has a 50 day moving average price of $6.42 and a 200-day moving average price of $6.15. The company has a debt-to-equity ratio of 0.92, a current ratio of 6.51 and a quick ratio of 6.51. The stock has a market cap of $735.00 million, a P/E ratio of -3.04 and a beta of 0.89. uniQure has a one year low of $3.73 and a one year high of $17.39.

uniQure (NASDAQ:QURE) last issued its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share for the quarter, topping the consensus estimate of ($1.12) by $0.21. The company had revenue of $2.29 million for the quarter, compared to analysts’ expectations of $2.73 million. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. On average, analysts predict that uniQure will post -3.74 EPS for the current year.

Insiders Place Their Bets

In other news, CEO Matthew C. Kapusta sold 3,418 shares of the business’s stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $7.63, for a total value of $26,079.34. Following the completion of the sale, the chief executive officer now owns 597,915 shares in the company, valued at approximately $4,562,091.45. The trade was a 0.57 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 4.74% of the company’s stock.

Institutional Trading of uniQure

A number of hedge funds have recently bought and sold shares of QURE. Point72 Asset Management L.P. raised its position in shares of uniQure by 336.1% in the 3rd quarter. Point72 Asset Management L.P. now owns 976,893 shares of the biotechnology company’s stock worth $4,816,000 after acquiring an additional 752,889 shares in the last quarter. Walleye Capital LLC purchased a new stake in shares of uniQure during the third quarter valued at about $444,000. Vanguard Group Inc. lifted its position in shares of uniQure by 11.4% during the first quarter. Vanguard Group Inc. now owns 1,072,536 shares of the biotechnology company’s stock valued at $5,577,000 after buying an additional 109,740 shares during the last quarter. Assenagon Asset Management S.A. lifted its position in shares of uniQure by 49.1% during the third quarter. Assenagon Asset Management S.A. now owns 271,346 shares of the biotechnology company’s stock valued at $1,338,000 after buying an additional 89,400 shares during the last quarter. Finally, Privium Fund Management B.V. lifted its position in shares of uniQure by 16.3% during the third quarter. Privium Fund Management B.V. now owns 744,916 shares of the biotechnology company’s stock valued at $3,672,000 after buying an additional 104,500 shares during the last quarter. Hedge funds and other institutional investors own 78.83% of the company’s stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.